Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions

Br J Dermatol. 2016 Dec;175(6):1251-1262. doi: 10.1111/bjd.14748. Epub 2016 Oct 12.

Abstract

Background: Recent studies have independently implicated the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, in the pathophysiology of Kaposi sarcoma (KS).

Objectives: We investigated whether the CXCL12/CXCR4-CXCR7 protein trio could constitute KS biomarkers.

Methods: Endothelial and spindle cells positive for CXCL12/CXCR4-CXCR7, human herpesvirus-8 latency-associated nuclear antigen (LANA), Ki67 antigen (proliferation) and vascular endothelial growth factor (VEGF) were quantitated in skin lesions from patients with AIDS-associated KS, patients with classic KS and patients with angiomas, using immunohistochemistry and quantitative image analysis (16, 21 and 20 skin lesions, respectively). Plasma CXCL12 concentrations were measured by enzyme-linked immunosorbent assay from 20 patients with AIDS-KS, 12 HIV-infected patients without KS and 13 healthy donors' samples.

Results: Cells positive for CXCL12, CXCR4, CXCR7, LANA, Ki67 and VEGF were significantly enriched in patients with AIDS-associated KS and classic KS vs. angiomas (P < 0·001), and in nodular vs. macular/papular KS lesions (P < 0·05). CXCL12, CXCR4 and CXCR7 detection correlated with LANA, Ki67 and VEGF detection (r > 0·4; P < 0·05). However, plasma CXCL12 concentrations did not differ between patients with AIDS-associated KS, HIV-infected patients without KS, and healthy donors.

Conclusions: The CXCL12/CXCR4-CXCR7 trio is upregulated in KS and correlates with KS pathophysiological markers and the severity of skin lesions. Histological assessment of the CXCL12 axis could serve as a valuable biomarker for KS diagnosis and progression.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use
  • Antigens, Viral / metabolism
  • Biomarkers, Tumor / metabolism*
  • Case-Control Studies
  • Chemokine CXCL12 / metabolism*
  • Female
  • Humans
  • Lenalidomide
  • Male
  • Nuclear Proteins / metabolism
  • Receptors, CXCR / metabolism*
  • Receptors, CXCR4 / metabolism*
  • Sarcoma, Kaposi / metabolism*
  • Skin Neoplasms / metabolism*
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • ACKR3 protein, human
  • Angiogenesis Inhibitors
  • Antigens, Viral
  • Biomarkers, Tumor
  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Nuclear Proteins
  • Receptors, CXCR
  • Receptors, CXCR4
  • Vascular Endothelial Growth Factor A
  • latency-associated nuclear antigen
  • Thalidomide
  • Lenalidomide